Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial
在接受抗PD-1/L1治疗后出现寡残留病灶的晚期非小细胞肺癌患者中,消融联合免疫疗法与单纯免疫疗法的疗效比较(BOOSTER):一项随机II期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02460-z
Yang, Shuo; Liu, Xinyu; Yu, Jia; Chen, Xiaoxia; Liu, Xiaozhen; Zhao, Sha; Jiang, Tao; Sun, Hui; Yang, Menghang; Wu, Fengying; Li, Aiwu; Wang, Lei; Gao, Guanghui; Xu, Yaping; Chen, Bin; Ren, Shengxiang